OBJECTIVE: Medium- and long-term sequelae of intravitreal bevacizumab (IVB) for type 1 retinopathy of prematurity (ROP) are uncertain. Our aim was to describe the fluorescein angiography (FA) findings in patients who received IVB as primary treatment for type 1 ROP and compare them to findings in patients with ROP that spontaneously regressed. DESIGN: Retrospective cohort. PARTICIPANTS: Twenty-eight patients with a history of ROP who underwent fluorescein angiography between December 1, 2013, and July 31, 2018. Patients were divided into 2 groups based on whether they had received IVB or had ROP that spontaneously regressed. METHODS: We reviewed the angiograms in the 2 groups for neovascularization (NV) and other abnormal vascular patterns in both the periphery and the posterior pole. MAIN OUTCOME MEASURES: Fluorescein angiography findings, including NV, peripheral, and macular vascular abnormalities. RESULTS: Forty eyes of 20 infants were included in the IVB group and 16 eyes of 8 infants in the untreated group. Median gestational age at birth was similar in the 2 groups (24.5 and 24.7 weeks, respectively; P = 0.44), as was the median birth weight (648.5 and 560.0 g, respectively; P = 0.26). Median postmenstrual age at the time of FA was 65.1 and 83.9 weeks, respectively (P = 0.0002). Review of angiograms demonstrated NV in 30.0% and 37.5% in the IVB and untreated cohorts, respectively (P = 0.75). Abnormal vascular patterns in the periphery were similar in both groups (100.0%), whereas posterior pole findings of vessels encroaching onto the fovea were more prevalent in the IVB cohort (65.0% vs. 25.0%; P = 0.009). CONCLUSIONS: Fluorescein angiography after bevacizumab for ROP reveals abnormal vascular patterns in all eyes and NV in approximately one-third. Similar abnormal vascular patterns on FA are seen at a similar prevalence after spontaneous regression of ROP. These findings suggest that the abnormal vascular patterns identified by FA in patients with ROP result from the disease process itself rather than as a result of exposure to anti-vascular endothelial growth factor medications.
OBJECTIVE: Medium- and long-term sequelae of intravitreal bevacizumab (IVB) for type 1 retinopathy of prematurity (ROP) are uncertain. Our aim was to describe the fluorescein angiography (FA) findings in patients who received IVB as primary treatment for type 1 ROP and compare them to findings in patients with ROP that spontaneously regressed. DESIGN: Retrospective cohort. PARTICIPANTS: Twenty-eight patients with a history of ROP who underwent fluorescein angiography between December 1, 2013, and July 31, 2018. Patients were divided into 2 groups based on whether they had received IVB or had ROP that spontaneously regressed. METHODS: We reviewed the angiograms in the 2 groups for neovascularization (NV) and other abnormal vascular patterns in both the periphery and the posterior pole. MAIN OUTCOME MEASURES: Fluorescein angiography findings, including NV, peripheral, and macular vascular abnormalities. RESULTS: Forty eyes of 20 infants were included in the IVB group and 16 eyes of 8 infants in the untreated group. Median gestational age at birth was similar in the 2 groups (24.5 and 24.7 weeks, respectively; P = 0.44), as was the median birth weight (648.5 and 560.0 g, respectively; P = 0.26). Median postmenstrual age at the time of FA was 65.1 and 83.9 weeks, respectively (P = 0.0002). Review of angiograms demonstrated NV in 30.0% and 37.5% in the IVB and untreated cohorts, respectively (P = 0.75). Abnormal vascular patterns in the periphery were similar in both groups (100.0%), whereas posterior pole findings of vessels encroaching onto the fovea were more prevalent in the IVB cohort (65.0% vs. 25.0%; P = 0.009). CONCLUSIONS:Fluorescein angiography after bevacizumab for ROP reveals abnormal vascular patterns in all eyes and NV in approximately one-third. Similar abnormal vascular patterns on FA are seen at a similar prevalence after spontaneous regression of ROP. These findings suggest that the abnormal vascular patterns identified by FA in patients with ROP result from the disease process itself rather than as a result of exposure to anti-vascular endothelial growth factor medications.
Authors: Jose M Garcia Gonzalez; Laura Snyder; Michael Blair; Ashley Rohr; Michael Shapiro; Mark Greenwald Journal: Retina Date: 2018-04 Impact factor: 4.256
Authors: Ramiro S Maldonado; Rachelle V O'Connell; Neeru Sarin; Sharon F Freedman; David K Wallace; C Michael Cotten; Katrina P Winter; Sandra Stinnett; Stephanie J Chiu; Joseph A Izatt; Sina Farsiu; Cynthia A Toth Journal: Ophthalmology Date: 2011-09-21 Impact factor: 12.079
Authors: Tiffany A Chen; Ryan A Shields; Zachary H Bodnar; Natalia F Callaway; Ira H Schachar; Darius M Moshfeghi Journal: Am J Ophthalmol Date: 2018-10-09 Impact factor: 5.258
Authors: Yoshihiro Yonekawa; Benjamin J Thomas; Aristomenis Thanos; Bozho Todorich; Kimberly A Drenser; Michael T Trese; Antonio Capone Journal: Retina Date: 2017-12 Impact factor: 4.256
Authors: Domenico Lepore; Graham E Quinn; Fernando Molle; Lorenzo Orazi; Antonio Baldascino; Marco H Ji; Maria Sammartino; Fabio Sbaraglia; Daniela Ricci; Eugenio Mercuri Journal: Ophthalmology Date: 2017-09-01 Impact factor: 12.079
Authors: Amir Sternfeld; Safa Rahmani; Jennifer L Rossen; David L Zhang; Yuping D Li; Victor L Quan; Russell Huang; Hawke H Yoon Journal: Graefes Arch Clin Exp Ophthalmol Date: 2021-12-01 Impact factor: 3.117
Authors: Martin Hložánek; Zbyněk Straňák; Zuzana Terešková; Jan Mareš; Inka Krejčířová; Marie Česká Burdová Journal: Diagnostics (Basel) Date: 2022-05-18
Authors: Domenico Lepore; Marco H Ji; Monica M Pagliara; Jacopo Lenkowicz; Nikola D Capocchiano; Luca Tagliaferri; Luca Boldrini; Vincenzo Valentini; Andrea Damiani Journal: Transl Vis Sci Technol Date: 2020-07-07 Impact factor: 3.283